Logo

Gene Synthesis Firm Sloning Gains $6.8M in European Series E Funding

Nov 06, 2007
NEW YORK (GenomeWeb News) - Sloning Biotechnology said today it has raised €4.7 million ($6.8 million) in Series E venture financing from one new and several previous investors.
 
Sloning, based in Puchheim, Germany, plans to use the cash to commercialize its Slonomics gene synthesis business internationally and to expand its Slonomax gene mutant library product line.
 
The round of funding included new investor LBBW Venture Capital and existing investors HBM BioVentures, KfW Bankengruppe, and Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft.
 
With the investment, LBBW’s Harold Poth will become a non-executive director at Sloning.
 
BioConnect of Frankfurt am Main, Germany, served as financial advisor to the company in the funding round.

Breaking News
The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.